Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (LSE/NYSE: HLN) covers the month of May 2026, with a specific reporting date of May 18, 2026. The filing serves as a notification and public disclosure under the UK Market Abuse Regulation regarding transactions by a Person Discharging Managerial Responsibilities (PDMR). Haleon operates as a consumer health company with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a regulatory disclosure of a specific share transaction rather than a financial results report.
Material Changes and Transaction Details
The filing discloses a specific transaction involving a PDMR:
- Individual: Alan Stewart, Senior Independent Non-Executive Director.
- Transaction Type: Acquisition of Ordinary Shares via dividend reinvestment.
- Date: May 14, 2026.
- Volume: 498 shares.
- Price: £3.3105 per share.
- Exchange: London Stock Exchange (XLON).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the standard regulatory disclosure of the PDMR transaction.
Key Facts for Investor Verification
- Verify the current share price of Haleon Plc on the London Stock Exchange to contextualize the £3.3105 transaction price.
- Confirm the total shareholding of Alan Stewart post-transaction to assess his overall exposure.
- Review the company's most recent Form 20-F or quarterly earnings release for actual financial performance metrics, as they are absent in this filing.